Urothelial Bladder Cancer | Oncology Today with Dr Neil Love: Management of Metastatic Urothelial Bladder Cancer (Companion Faculty Lecture)
Featuring a slide presentation and related discussion from Dr Michiel van der Heijden, including the following topics: Efficacy and safety data from the Phase III EV-302/KEYNOTE-A39 trial comparing enfortumab vedotin/pembrolizumab to chemotherapy for patients with previously untreated metastatic urothelial bladder cancer (mUBC) (0:00) Principal findings from the Phase III CheckMate 901 substudy of nivolumab in combination with chemotherapy and continued as monotherapy compared to chemotherapy alone as first-line treatment for cisplatin-eligible patients with mUBC (14:36) Key data from the Phase III THOR trial of erdafitinib for patients with relapsed mUBC and susceptible FGFR3 or FGFR2 genetic alterations (22:03) Long-term findings with sacituzumab govitecan for patients with progressive mUBC; emerging data from the Phase III TROPiCS-04 study (29:43) Outcomes observed in the cohort of patients with mUBC in the Phase II DESTINY-PanTumor02 trial of trastuzumab deruxtecan (36:19) CME information and select publications